Balchem Corporation

Balchem Corporation(BCPC)の株式分析

$170.530

+0.068 (+0.04%)終値時点

Loading chart…
高値
174.290
始値
172.060
出来高加重平均価格
171.71
出来高
349.11K
時価総額
4.92B
安値
170.310
売買代金
59.95M
EV/EBITDA(TTM)
18.63

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.

balchem.com

AI分析 of Balchem Corporation (BCPC)

買い

Balchem Corp is a good buy right now due to its strong financial performance and positive market sentiment. The current price is $167.83, with a forward P/E ratio of 29.33, indicating growth potential. The company reported a 11.2% year-over-year revenue increase in Q2 2026, reaching $284 million, and a gross margin of 36.5%, which reflects robust profitability. However, a risk to consider is the significant insider selling, which has increased by 1060.90% over the last month, potentially signaling caution among insiders.

バリュエーション指標

Balchem Corporation(BCPC)の現在の予想PERは29.33で、5年平均は32.65です。

予想PER

適正
5年平均 P/E
32.65
現在のP/E
29.33
割高
36.01
割安
29.30

予想EV/EBITDA

適正
5年平均 EV/EBITDA
20.55
現在のEV/EBITDA
18.63
割高
22.64
割安
18.47

予想PSR

適正
5年平均 P/S
4.78
現在のP/S
4.54
割高
5.36
割安
4.20

Alphio AI による BCPC の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%BCPC

$162.17

シナリオ価格

基

基本

基本 · 50%BCPC

$159.96

シナリオ価格

弱

弱気

弱気 · 25%BCPC

$150.29

シナリオ価格

BCPC を保有するクジラ

S

Salem Investment Counselors, Inc.

+ を保有BCPC

+6.48%

3か月リターン

W

Wasatch Advisors LP

+ を保有BCPC

+0.81%

3か月リターン

N

Nationwide Fund Advisors

+ を保有BCPC

+0.44%

3か月リターン

イベントタイムライン

2026-07-31 (ET)

07:31:00

Balchem Reports Q2 Revenue of $284M

2026-04-30 (ET)

07:50:00

Balchem Q1 Revenue $270.71M Beats Consensus

2026-03-09 (ET)

08:20:00

Balchem Launches Metalosate T.E.A.M. Plant Tissue Analysis Platform

2026-02-20 (ET)

07:20:00

Balchem Reports Q4 Revenue of $263.6M

2025-12-22 (ET)

08:10:00

Eastman and Balchem Welcome EU's Anti-Dumping Duties on Choline Chloride Imports from China

ニュース

BCPC のよくある質問 — Alphio AI が回答

Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia. It operates in the Basic Materials sector (CHEMICALS & ALLIED PRODUCTS industry).

Balchem Corp is a good buy right now due to its strong financial performance and positive market sentiment. The current price is $167.83, with a forward P/E ratio of 29.33, indicating growth potential. The company reported a 11.2% year-over-year revenue increase in Q2 2026, reaching $284 million, and a gross margin of 36.5%, which reflects robust profitability. However, a risk to consider is the significant insider selling, which has increased by 1060.90% over the last month, potentially signaling caution among insiders.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める